- Conditions
- Pain, Abuse, Drug
- Interventions
- Active Cannabis, Placebo Cannabis
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Location Directory
Clinical trials in Los Angeles, California
This page shows live ClinicalTrials.gov search results for Los Angeles, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
4634
Shown on this page
12
Current sort
Recently updated
Location scope
Los Angeles, CA
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 157–168 of 4,634 matching trials in Los Angeles, CA.
Live ClinicalTrials.gov results.
Institutions in Los Angeles
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Hypertension
- Interventions
- lorundrostat, Placebo
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 128
- States / cities
- Birmingham, Alabama • Foley, Alabama • Chandler, Arizona + 101 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 390
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more
- Conditions
- Severe Alopecia Areata
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Miami, Florida • Meridian, Idaho + 6 more
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Placebo, Olpasiran
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 7,297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 102 more
- Conditions
- Hemophilia
- Interventions
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Drug · Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 1 Year to 11 Years · Male only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Orange, California • Torrance, California + 4 more
- Conditions
- Dravet Syndrome
- Interventions
- LP352, Placebo
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Oral Azacitidine, Positron Emission Tomography, Prednisone, Questionnaire Administration, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 75 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 176
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more
- Conditions
- Chronic Hepatitis D Infection
- Interventions
- Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg
- Drug
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 10
- States / cities
- Long Beach, California • Los Angeles, California • Chicago, Illinois + 4 more
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 366 Days to 46 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 145
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more
- Conditions
- Fetal Alcohol Spectrum Disorders, Attention Deficit Hyperactivity Disorder
- Interventions
- Trigeminal Nerve Stimulation (TNS)
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 8 Years to 12 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Orelabrutinib, Placebo
- Drug
- Lead sponsor
- Zenas BioPharma (USA), LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 22 more